4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
February 05, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of...
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 05, 2024 08:00 ET
|
Coherus BioSciences, Inc.
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be...
Ophthalmic Equipment Market is Expected to Reach $88.5 Billion | MarketsandMarkets™
February 05, 2024 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ophthalmic Equipment market in terms of revenue was estimated to be worth $66.2 billion in 2023 and is poised to reach $88.5 billion by 2029, growing at a...
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
February 03, 2024 17:00 ET
|
4D Molecular Therapeutics, Inc.
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12...
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
February 03, 2024 16:20 ET
|
EyePoint Pharmaceuticals, Inc.
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary...
Regenerative Medicine Market projected to reach USD 108.7 Billion by 2030, growing at a CAGR of 23.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study
February 02, 2024 10:45 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 02, 2024 (GLOBE NEWSWIRE) -- According to a research report "Regenerative Medicine Market", by Product (Cell therapy, Stem cell therapy [Cell transplantations, Stem cell therapy...
Uveal Melanoma Market Size & Share to Exceed USD 2.5 Billion by 2034, at CAGR of 5.9%. "Shining a Light on Innovation: Revolutionizing the Uveal Melanoma Market for Brighter Tomorrows" – PMI Leads the Way
February 01, 2024 20:30 ET
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Uveal Melanoma Market size was valued at about USD 1.5 Billion in 2024 and expected to grow at CAGR of 5.9% to...
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
February 01, 2024 17:30 ET
|
Adverum Biotechnologies, Inc.
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with...
Ophthalmic Devices Sector: Comprehensive Analysis Reveals Accelerated Growth in Corneal Implants Market Through 2033
February 01, 2024 11:05 ET
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Corneal Implants Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033" report has been added to ...
Hyaluronic Acid Raw Material Market Set to Reach USD 14.23 Billion by 2034 with Prominent Growth in Asia Pacific and Cosmetic Applications
February 01, 2024 09:41 ET
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Global Hyaluronic Acid Raw Material Market Analysis & Forecast To 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...